Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor Overactivity
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor Overactivity ; volume:48 ; number:3 ; day:9 ; month:3 ; year:2023 ; pages:257-269 ; date:5.2023
European journal of drug metabolism and pharmacokinetics ; 48, Heft 3 (9.3.2023), 257-269, 5.2023
- Creator
-
Sano, Yamato
Shoji, Satoshi
Shahin, Mohamed
Sweeney, Kevin
Darekar, Amanda
Malhotra, Bimal K.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s13318-023-00818-8
- URN
-
urn:nbn:de:101:1-2023090713130018875217
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Sano, Yamato
- Shoji, Satoshi
- Shahin, Mohamed
- Sweeney, Kevin
- Darekar, Amanda
- Malhotra, Bimal K.
- SpringerLink (Online service)
Other Objects (12)
Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance
Pharmacokinetic-pharmacodynamic modeling of tylosin against Streptococcus suis in pigs
Dose Rationale of Nasal Glucagon in Japanese Pediatric Patients with Diabetes Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation
Correction to: Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance
Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia
Pharmacokinetic–pharmacodynamic modeling of maintenance therapy for childhood acute lymphoblastic leukemia
Physiologically-based pharmacokinetic/pharmacodynamic modeling of meropenem in critically ill patients
Pharmacokinetic-pharmacodynamic modeling of antibacterial agents in tissues and body fluids
Pharmacokinetic-Pharmacodynamic Modeling for Coptisine Challenge of Inflammation in LPS-Stimulated Rats
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat
A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim
Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance
Pharmacokinetic-pharmacodynamic modeling of tylosin against Streptococcus suis in pigs
Dose Rationale of Nasal Glucagon in Japanese Pediatric Patients with Diabetes Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation
Correction to: Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance
Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia
Pharmacokinetic–pharmacodynamic modeling of maintenance therapy for childhood acute lymphoblastic leukemia
Physiologically-based pharmacokinetic/pharmacodynamic modeling of meropenem in critically ill patients
Pharmacokinetic-pharmacodynamic modeling of antibacterial agents in tissues and body fluids
Pharmacokinetic-Pharmacodynamic Modeling for Coptisine Challenge of Inflammation in LPS-Stimulated Rats
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat
A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim
Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance
Pharmacokinetic-pharmacodynamic modeling of tylosin against Streptococcus suis in pigs
Dose Rationale of Nasal Glucagon in Japanese Pediatric Patients with Diabetes Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation
Correction to: Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance
Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia
Pharmacokinetic–pharmacodynamic modeling of maintenance therapy for childhood acute lymphoblastic leukemia
Physiologically-based pharmacokinetic/pharmacodynamic modeling of meropenem in critically ill patients
Pharmacokinetic-pharmacodynamic modeling of antibacterial agents in tissues and body fluids
Pharmacokinetic-Pharmacodynamic Modeling for Coptisine Challenge of Inflammation in LPS-Stimulated Rats
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat